M
MEDP
MEDPUnverified6 segments tracked|7 years of data|Annual (10-K)
Total Revenue
$2.1B11.8%
FY2024
Operating Segments
6Active segments
Blended Margin
0.0%Operating margin
Highest Margin
0.0%Oncology
Segment Shift
Oncology has grown from 28.3% to 30.9% of total revenue since FY2018, with 0.0% operating margins. Meanwhile, Metabolic is the fastest growing at +21.4% YoY.
Segment Revenue Over Time
Revenue Mix
Segment Breakdown — FY2024
| Segment | Revenue | Op. Income | Margin | % of Total | YoY |
|---|---|---|---|---|---|
| Oncology | $651M | $0 | 0.0% | 30.9% | +10.9% |
| Metabolic | $458M | $0 | 0.0% | 21.7% | +21.4% |
| Other | $431M | $0 | 0.0% | 20.5% | +6.6% |
| Cardiology | $230M | $0 | 0.0% | 10.9% | +19.0% |
| Central Nervous System | $182M | $0 | 0.0% | 8.6% | +13.7% |
| Antiviral And Anti Infective | $156M | $0 | 0.0% | 7.4% | -4.2% |
Want more? Unlock the full analysis.
Sign up free to access quarterly data, financial statements, trend analysis, geographic segments, Excel exports, and cross-company comparisons.
Get Started Free